| Date Filed | Type | Description |
| 10/10/2023 |
8-K
| Other Events Interactive Data |
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/08/2023 |
8-K
| Quarterly results |
| 07/10/2023 |
SC 13G/A
| FMR LLC reports a 15% stake in AVIDITY BIOSCIENCES INC |
| 07/10/2023 |
8-K
| Regulation FD Disclosure, Other Events Interactive Data |
| 06/16/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 05/17/2023 |
8-K
| Other Events Interactive Data |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/27/2023 |
8-K
| Quarterly results |
| 03/30/2023 |
8-K
| Quarterly results |
| 03/17/2023 |
4
| LEVIN ARTHUR A (Director) has filed a Form 4 on Avidity Biosciences, Inc.|
Txns:
| Sold 100 shares
@ $22.01, valued at
$2.2k
Exercised 100 options to buy
@ $1.24, valued at
$124 |
|
| 02/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 02/28/2023 |
8-K
| Quarterly results |
| 02/23/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/14/2023 |
SC 13G/A
| EcoR1 Capital, LLC reports a 0% stake in Avidity Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| PRICE T ROWE ASSOCIATES INC reports a 10.1% stake in AVIDITY BIOSCIENCES INC |
| 02/09/2023 |
SC 13G
| VANGUARD GROUP INC reports a 5.2% stake in Avidity Biosciences Inc. |
| 02/09/2023 |
SC 13G/A
| FMR LLC reports a 7.4% stake in AVIDITY BIOSCIENCES INC |
| 02/03/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/03/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 02/02/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 01/24/2023 |
4
| Boyce Sarah (President and CEO) has filed a Form 4 on Avidity Biosciences, Inc.|
Txns:
| Granted 50,000 shares
@ $0
Granted 400,000 options to buy
@ $22.47, valued at
$9M
|
|
| 01/24/2023 |
4
| Flanagan W. Michael (Chief Technical Officer) has filed a Form 4 on Avidity Biosciences, Inc.|
Txns:
| Granted 40,000 shares
@ $0
Granted 144,000 options to buy
@ $22.47, valued at
$3.2M
|
|
| 01/24/2023 |
4
| LEVIN ARTHUR A (Chief Scientific Officer) has filed a Form 4 on Avidity Biosciences, Inc.|
Txns:
| Granted 18,000 shares
@ $0
Granted 144,000 options to buy
@ $22.47, valued at
$3.2M
|
|
| 01/24/2023 |
4
| MacLean Michael F (CFO) has filed a Form 4 on Avidity Biosciences, Inc.|
Txns:
| Granted 18,500 shares
@ $0
Granted 148,000 options to buy
@ $22.47, valued at
$3.3M
|
|
| 01/24/2023 |
4
| McCarthy Teresa (Chief Human Resources Officer) has filed a Form 4 on Avidity Biosciences, Inc.|
Txns:
| Granted 20,000 shares
@ $0
Granted 108,000 options to buy
@ $22.47, valued at
$2.4M
|
|
| 01/17/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/11/2023 |
SC 13G/A
| Cowen Financial Products LLC reports a 6.4% stake in Avidity Biosciences, Inc |
| 01/03/2023 |
4
| LEVIN ARTHUR A (Chief Scientific Officer) has filed a Form 4 on Avidity Biosciences, Inc.|
Txns:
| Sold 40,000 shares
@ $22.0142, valued at
$880.6k
Exercised 40,000 options to buy
@ $1.24, valued at
$49.6k
|
|
| 12/30/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/27/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
|